Company intelligence / Profile preview

Hainan Zhongshenghemei Biopharmaceutical

Haikou, Hainan, China

Ownership: Private
Employees: ~60
Development stage: Other

Overview

Hainan Zhongshenghemei is a clinical-stage biotechnology company specialized in the development of innovative peptide-based therapeutics for metabolic and endocrine disorders. Its lead candidate, ZSHM-001, has shown promising safety and efficacy profiles in early clinical trials as a long-acting GLP-1 receptor agonist for blood glucose control and weight management.

Therapeutic areas: EndocrinologyGastroenterology
Modalities: PeptidesBiologic
Industry: Biotech

Beyond the preview

Go deeper on Hainan Zhongshenghemei Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hainan Zhongshenghemei Biopharmaceutical.

Explore the full profile